Literature DB >> 32928465

A Survey-Based Needs Assessment of Barriers to Optimal Sickle Cell Disease Care in the Emergency Department.

Elizabeth A Linton1, Dania A Goodin2, Jane S Hankins3, Julie Kanter4, Liliana Preiss5, Jena Simon6, Kimberly Souffront7, Paula Tanabe8, Robert Gibson9, Lewis L Hsu10, Allison King11, Lynne D Richardsona12, Jeffrey A Glassberg1.   

Abstract

STUDY
OBJECTIVE: Guided by an implementation science framework, this needs assessment identifies institutional-, provider-, and patient-level barriers to care of sickle cell disease (SCD) in the emergency department (ED) to inform future interventions conducted by the multicenter Sickle Cell Disease Implementation Consortium.
METHODS: The consortium developed and implemented a validated needs assessment survey administered to a cross-sectional convenience sample of patients with SCD and ED providers caring for them. In total, 516 adolescents and adults with SCD and 243 ED providers from 7 and 5 regions of the United States, respectively, responded to the ED care delivery for SCD survey.
RESULTS: Survey results demonstrated that 84.5% of respondents with SCD have an outpatient provider who treats many patients with SCD. In the ED, 54.3% reported not receiving care fast enough and 46.0% believed physicians did not care about them and believed similarly of nurses (34.9%). Consequently, 48.6% of respondents were "never" or "sometimes" satisfied with their ED care. Of surveyed ED providers, 75.1% were unaware of the National Heart, Lung, and Blood Institute recommendations for vaso-occlusive crises, yet 98.1% were confident in their knowledge about caring for patients with SCD. ED providers identified the following factors as barriers to care administration: opioid epidemic (62.1%), patient behavior (60.9%), crowding (58.0%), concern about addiction (47.3%), and implicit bias (37.0%).
CONCLUSION: The results underscore that many patients with SCD are dissatisfied with their ED care and highlight challenges to optimal care on the practice, provider, and patient levels. Exploring these differences may facilitate improvements in ED care.
Copyright © 2020 American College of Emergency Physicians. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2020        PMID: 32928465      PMCID: PMC7511000          DOI: 10.1016/j.annemergmed.2020.08.013

Source DB:  PubMed          Journal:  Ann Emerg Med        ISSN: 0196-0644            Impact factor:   5.721


  13 in total

1.  Emergency department visits made by patients with sickle cell disease: a descriptive study, 1999-2007.

Authors:  Hussain R Yusuf; Hani K Atrash; Scott D Grosse; Christopher S Parker; Althea M Grant
Journal:  Am J Prev Med       Date:  2010-04       Impact factor: 5.043

Review 2.  Hydroxyurea in sickle cell disease: drug review.

Authors:  Rohit Kumar Agrawal; Rakesh Kantilal Patel; Varsha Shah; Lalit Nainiwal; Bhadra Trivedi
Journal:  Indian J Hematol Blood Transfus       Date:  2013-05-24       Impact factor: 0.900

3.  Health professional perceptions of opioid dependence among patients with pain.

Authors:  R D Waldrop; C Mandry
Journal:  Am J Emerg Med       Date:  1995-09       Impact factor: 2.469

4.  Experiences of hospital care and treatment seeking for pain from sickle cell disease: qualitative study.

Authors:  K Maxwell; A Streetly; D Bevan
Journal:  BMJ       Date:  1999-06-12

5.  PROMIS®-29 v2.0 profile physical and mental health summary scores.

Authors:  Ron D Hays; Karen L Spritzer; Benjamin D Schalet; David Cella
Journal:  Qual Life Res       Date:  2018-03-22       Impact factor: 4.147

6.  National study of barriers to timely primary care and emergency department utilization among Medicaid beneficiaries.

Authors:  Paul T Cheung; Jennifer L Wiler; Robert A Lowe; Adit A Ginde
Journal:  Ann Emerg Med       Date:  2012-03-13       Impact factor: 5.721

7.  Mortality rates and age at death from sickle cell disease: U.S., 1979-2005.

Authors:  Sophie Lanzkron; C Patrick Carroll; Carlton Haywood
Journal:  Public Health Rep       Date:  2013 Mar-Apr       Impact factor: 2.792

8.  Ethnic differences in pain and pain management.

Authors:  Claudia M Campbell; Robert R Edwards
Journal:  Pain Manag       Date:  2012-05

9.  Racial bias in pain assessment and treatment recommendations, and false beliefs about biological differences between blacks and whites.

Authors:  Kelly M Hoffman; Sophie Trawalter; Jordan R Axt; M Norman Oliver
Journal:  Proc Natl Acad Sci U S A       Date:  2016-04-04       Impact factor: 11.205

10.  The sickle cell disease implementation consortium: Translating evidence-based guidelines into practice for sickle cell disease.

Authors:  Lisa D DiMartino; Ana A Baumann; Lewis L Hsu; Julie Kanter; Victor R Gordeuk; Jeffrey Glassberg; Marsha J Treadwell; Cathy L Melvin; Joseph Telfair; Lisa M Klesges; Allison King; Ted Wun; Nirmish Shah; Robert W Gibson; Jane S Hankins
Journal:  Am J Hematol       Date:  2018-10-17       Impact factor: 13.265

View more
  4 in total

1.  Systematic online academic resources (SOAR) review: Sickle cell disorders.

Authors:  Sara Alavian; Prince Asare-Agbo; Teresa M Chan
Journal:  AEM Educ Train       Date:  2022-10-13

2.  Identifying barriers to evidence-based care for sickle cell disease: results from the Sickle Cell Disease Implementation Consortium cross-sectional survey of healthcare providers in the USA.

Authors:  Matthew P Smeltzer; Kristen E Howell; Marsha Treadwell; Liliana Preiss; Allison A King; Jeffrey A Glassberg; Paula Tanabe; Sherif M Badawy; Lisa DiMartino; Robert Gibson; Julie Kanter; Lisa M Klesges; Jane S Hankins
Journal:  BMJ Open       Date:  2021-11-17       Impact factor: 2.692

Review 3.  Moving Toward a Multimodal Analgesic Regimen for Acute Sickle Cell Pain with Non-Opioid Analgesic Adjuncts: A Narrative Review.

Authors:  Martha O Kenney; Wally R Smith
Journal:  J Pain Res       Date:  2022-03-31       Impact factor: 3.133

4.  Perspectives of individuals with sickle cell disease on barriers to care.

Authors:  Shannon Phillips; Yumei Chen; Rita Masese; Laurence Noisette; Kasey Jordan; Sara Jacobs; Lewis L Hsu; Cathy L Melvin; Marsha Treadwell; Nirmish Shah; Paula Tanabe; Julie Kanter
Journal:  PLoS One       Date:  2022-03-23       Impact factor: 3.752

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.